Dade Behring sets up Korean joint venture:
This article was originally published in Clinica
Executive Summary
Dade Behring has formed a joint venture with Handok Pharmaceutical in South Korea to market and distribute lab equipment and reagents. The new company, Dade Behring Handok Diagnostics, will market Dade Behring's full line of products as well as the Eppendorf brand of precision products and will replace the company's multiple distribution channels. Dade will be the majority owner of the new company. Handok's CEO and president, Young Kim, will be executive director of the new company, while Dade's Patrick Chiu will be general manager and representative director and KiHyun Koh of Handok's diagnostics division will be representative director and will handle on-site daily operations.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.